诺禾致源NOVOGENE品牌怎么样 申请店铺

我要投票 诺禾致源NOVOGENE在医疗器械行业中的票数:358 更新时间:2025-06-30
诺禾致源NOVOGENE是哪个国家的品牌?「诺禾致源NOVOGENE」是 北京诺禾致源科技股份有限公司 旗下著名品牌。该品牌发源于北京,由创始人李瑞强在2011-03-15期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺禾致源NOVOGENE品牌出海!将品牌入驻外推网,定制诺禾致源NOVOGENE品牌推广信息,可以显著提高诺禾致源NOVOGENE产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺禾致源NOVOGENE怎么样

北京诺禾致源科技股份有限公司于2011年3月在北京中关村生命科学园注册成立,专注于开拓前沿分子生物学技术和高性能计算在生命科学研究和人类健康领域的应用,致力于成为全球领先的基因组学产品和服务提供者。企业总部位于北京,在天津、南京、美国和新加坡设有实验室或实验基地,并在香港、美国和英国设有子公司,办公面积逾26'000m2。

诺禾致源目前已经成为全球较大测序服务中心,每年可完成200'000人全基因组测序的超高通量。诺禾致源引入的测序平台包括10台PacBioSequel、25台HiSeqX、10台HiSeq2000/2500、4台MiSeq、1台HiSeq4000、4台NextSeq500和6台LifeIonProton(DA8600);而全球领先的高性能计算平台和数据中心运算能力达到了878Tflops,总内存368TB,总存储26.8PB,有效地支撑着生命科学研究和医疗健康两大领域对大数据分析和存储的需求。

目前,诺禾致源现已建立一支来自海内外顶级名校、多学科交叉型的高素质综合团队,其中硕士及其以上学历占比近68%。以创始人李瑞强博士为首建立的生物信息学专业分析团队以技术产品开发为导向,在分子病理学、肿瘤诊治和遗传病检测及大数据整合等多个层面积累了丰富的经验。

诺禾致源的业务覆盖科技服务、肿瘤基因检测及遗传检测等领域,为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供基因测序和生物信息技术支持等服务。肿瘤检测依托完整的分子病理检测平台,面向患者、医院和药企提供精准的实体瘤分子病理检测产品与服务,以深度基因测序和大数据分析解读为核心,持续开发国际领先的肿瘤基因检测产品,提供肿瘤用药指导、动态监测、肿瘤遗传易感基因检测等肿瘤精准治疗解决方案。在遗传检测方面诺禾致源已开发一系列基于二代测序技术的检测服务,包括孕前基因检测,新生儿基因筛查,个人基因组等产品,致力于开拓基因组学在人类健康领域的应用,专注于生殖健康和个人基因组领域,并为客户提供专业的遗传咨询服务。


Beijing Nuohe Zhiyuan Technology Co., Ltd. was registered and established in Zhongguancun Life Science Park in March 2011. It focuses on exploring the application of cutting-edge molecular biology technology and high-performance computing in the field of life science research and human health, and is committed to becoming a leading global provider of genomic products and services. Headquartered in Beijing, the company has laboratories or experimental bases in Tianjin, Nanjing, the United States and Singapore, and subsidiaries in Hong Kong, the United States and the United Kingdom, with an office area of more than 26'000m2. At present, Nuohe Zhiyuan has become the largest sequencing service center in the world, which can complete the ultra-high throughput sequencing of the whole genome of 200'000 people every year. The sequencing platform introduced by Nuohe Zhiyuan includes 10 pacbiosequels, 25 hiseqx, 10 hiseq2000 / 2500, 4 miseq, 1 hiseq4000, 4 nextseq500 and 6 lifeionproton (da8600); the world's leading high-performance computing platform and data center have computing power of 878tflops, total memory of 368tb, total storage of 26.8pb, which effectively supports life science research and medical health The demand of big data analysis and storage in large fields. At present, Nuohe Zhiyuan has established a high-quality comprehensive team from top universities at home and abroad, with a master's degree or above accounting for nearly 68%. The bioinformatics professional analysis team, led by the founder Dr. Li Ruiqiang, has accumulated rich experience in molecular pathology, tumor diagnosis and treatment, genetic disease detection, big data integration and many other layers, guided by technical product development. Nuohe Zhiyuan's business covers science and technology services, tumor gene detection, genetic detection and other fields, providing gene sequencing and bio information technology support services for global research universities, scientific research institutes, hospitals, pharmaceutical R & D enterprises, agricultural enterprises, etc. Tumor detection relies on a complete molecular pathology detection platform to provide patients, hospitals and pharmaceutical companies with accurate solid tumor molecular pathology detection products and services. With in-depth gene sequencing and big data analysis and interpretation as the core, it continues to develop internationally leading tumor gene detection products, providing tumor medication guidance, dynamic monitoring, tumor genetic susceptibility gene detection and other tumor precise treatment Solution. In terms of genetic testing, Nuohe Zhiyuan has developed a series of testing services based on second-generation sequencing technology, including pre pregnancy gene testing, newborn gene screening, personal genome and other products, committed to exploring the application of genomics in the field of human health, focusing on the field of reproductive health and personal genome, and providing professional genetic consulting services for customers.

本文链接: https://brand.waitui.com/d899c7460.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

朗迪集团:拟以不超1.21亿元收购聚嘉科技不超过20.1667%股权

36氪获悉,朗迪集团公告,公司拟以现金方式收购宁波聚嘉新材料科技有限公司不超过20.1667%的股权,总价不超过1.21亿元。宁波聚嘉新材料科技有限公司是目前行业内唯一具备从高性能LCP纤维级基体树脂、改性树脂到高性能LCP纤维全产业链规模化生产及研发能力的高科技企业。LCP作为一种高端特种工程材料,在航空航天、工业输送、光缆电缆、高端绳缆等关键领域应用广泛,市场前景广阔。

2分钟前

茉莉奶白洛杉矶首店首月销售额突破419.5万元

36氪获悉,茉莉奶白洛杉矶首店首月销售额突破419.5万元,售出超77144杯,刷新记录。

2分钟前

港股新火科技定增2.75亿港元,翁晓奇控股公司成最大认购方

36氪获悉,今日,港股上市公司新火科技公告,公司将向5名投资者定向增发合计约1.66亿股新股,每股1.66港元,预计募资总额约为2.75亿港元。受此影响,6月30日新火科技在午后涨幅扩大逾38%,报3.25港元。本轮定增主要认购方包括Avenir Investment、LINEX Holdings Ltd、TX Capital Holdings Ltd、Night Wood 及 Rosen Holdings Ltd等。其中LINEX认购金额达1.24亿港元,成最大认购方,交易完成后将持有新火科技约10%的股份。

2分钟前

深中通道西人工岛将开放旅游

36氪获悉,据深圳发布,2025年6月30日上午,在深中通道开通运营一周年之际,广东交通集团与深圳市文化广电旅游体育局就深中通道西人工岛投资开发暨战略合作签约,共同推动深中通道从“交通枢纽”向“综合地标”跨越升级。双方将围绕西人工岛文旅项目深度合作,融合科普教育、主题观光、研学体验等多元业态,打造粤港澳大湾区“科技+工程+文旅”复合型文旅项目。

2分钟前

耐普矿机:签订1.35亿元标准供货合同

36氪获悉,耐普矿机公告,近日与哈萨克斯坦共和国某矿业公司旗下两处矿山项目签订了《标准供货合同》,合同金额合计1885.25万美元,折合人民币约1.35亿元。

2分钟前

本页详细列出关于诺禾致源NOVOGENE的品牌信息,含品牌所属公司介绍,诺禾致源NOVOGENE所处行业的品牌地位及优势。
咨询